RxDoctor Payments Data

Dipan Shah, MD

Cardiovascular Disease · Houston, TXNPI 1114966470

Payments from drug & device makers

$388,064in general payments, 2019–2025

Across 277 payments — averaging $1400.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Guerbet LLC$224K
  • Siemens Medical Solutions USA, Inc.$87K
  • Kiniksa Pharmaceuticals, Ltd.$37K
  • AstraZeneca$17K
  • Kiniksa Pharmaceuticals International, PLC$15K
  • Amgen$5K
  • plus $3K from 22 others

What the payments were for

  • Consulting fees$5,8997%
  • Speaking & faculty fees$45,13350%
  • Travel & lodging$33,08137%
  • Food & beverage$5,7516%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$388,064 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$79,760
Medicare patients
377
Services billed
1,477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$52,287
EntrestoSacubitril/Valsartan19$28,652
FarxigaDapagliflozin Propanediol11$14,014
Ranolazine ErRanolazine12$1,545
Rosuvastatin Calcium82$1,202
Metoprolol Succinate57$1,070
Ezetimibe36$930
Carvedilol65$722
Atorvastatin Calcium58$689
Furosemide42$322
Losartan Potassium32$280
ClopidogrelClopidogrel Bisulfate12$267
Ramipril11$234
Spironolactone19$220
Amlodipine Besylate18$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$284$52,28736 claims
NovartisEntresto$385$28,65219 claims
AstraZenecaFarxiga$16,973$14,01411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →